{
  "abstract": "Long chain polyunsaturated omega-3 fatty acids (n-3 FA), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are known to be important components in a healthy diet and contribute to healthy functioning of the heart and the brain, among other organs. Although there are epidemiological studies on the strong relationship between fish or n-3 FA consumption and lower risk of cognitive decline, results from randomized controlled trials (RCTs) are less consistent. Here, we performed a scoping review on RCTs with n-3 FA supplementation where cognition was evaluated. Seventy-eight RCTs published before April 2022 were included in this review. Among these RCTs, 43.6% reported a positive cognitive outcome after the consumption of n-3 FA compared to the placebo. However, there was a large diversity of populations studied (age ranges and health status), wide range of doses of EPA + DHA supplemented (79 mg/day - 5200 mg/day) and a multitude of tests evaluating cognition, mainly diagnostic tests, that were used to assess cognitive scores and overall cognitive status. RCTs were thereafter categorized into non-cognitively impaired middle-aged adults (n = 24), non-cognitively impaired older adults (n = 24), adults with subjective memory complaints (n = 14), adults with mild cognitive impairments (MCI, n = 9) and people with diagnosed dementia or other cognitive changes (n = 7). Among these categories, 66.7% of RCTs conducted with MCI adults reported a positive cognitive outcome when supplemented with n-3 FA vs. the placebo. Therefore, this scoping review provides rationale and questions to a) strengthen the design of future RCTs with n-3 FA for cognitive outcomes, and b) generate more informative data to support clinicians in their practice in assessing cognition before and after a nutritional intervention.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "name": "B. Andriambelo"
    },
    {
      "name": "M. Stiffel"
    },
    {
      "name": "K. Roke"
    },
    {
      "name": "Melanie Plourde"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/6wzqrn94d43y8.bib",
  "cited_by": 43,
  "doi": "10.1016/j.arr.2022.101835",
  "fulltext_url": null,
  "id": "6wzqrn94d43y8",
  "issns": [
    "1872-9649"
  ],
  "landing_url": "https://hal.science/hal-05790356v1",
  "language": "en",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "openalex",
      "2916|Fatty Acid Research and Health"
    ]
  ],
  "openalex": "W4313479328",
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-09",
  "publisher": "Elsevier Masson",
  "ris": "https://research.draconitic.com/paper/6wzqrn94d43y8.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:53Z",
      "native_id": "hal-05790356",
      "source": "hal",
      "url": "https://hal.science/hal-05790356v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:0.sdv",
      "subfield": "general"
    }
  ],
  "title": "New perspectives on randomized controlled trials with omega-3 fatty acid supplements and cognition: A scoping review",
  "title_text": "New perspectives on randomized controlled trials with omega-3 fatty acid supplements and cognition: A scoping review",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:53Z",
  "url": "https://research.draconitic.com/paper/6wzqrn94d43y8",
  "venue": "Ageing Research Reviews - ARR",
  "versions": []
}